Inovio Pharmaceuticals (INO) Cash from Operations (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Cash from Operations of 21591316.0 for Q1 2026, down 11.46% sequentially from 19370549.0 in Q4 2025, and up 19.66% YoY from 18044293.21 in Q1 2025.
Inovio Pharmaceuticals (INO) Cash from Operations (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Cash from Operations for 17 years, with the latest figure at 21591316.0 in Q1 2026.
- Quarterly Cash from Operations rose 19.66% year-over-year to 21591316.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 83346719.0 (up 18.44% YoY) and the FY2025 annual result came in at 88629430.0, up 14.84% from the prior year.
- Cash from Operations retreated to 21591316.0 in Q1 2026 per INO's latest filing, from 19370549.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 19370549.0 in Q4 2025 and troughed at 67465314.0 in Q3 2022.
- A 5-year average of 32639898.29 and a median of 28209350.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations plunged 45.12% in 2022, then jumped 56.85% in 2023.
- Over 5 years, Cash from Operations stood at 36340032.0 in 2022, then advanced by 27.69% to 26275785.0 in 2023, then advanced by 25.16% to 19663909.0 in 2024, then grew by 1.49% to 19370549.0 in 2025, then slipped by 11.46% to 21591316.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 21591316.0, 19370549.0, and 21573495.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | -18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.05 Mn |
| Jun 30, 2026 | -18.05 Mn |
| Mar 31, 2026 | -21.59 Mn |
| Mar 31, 2026 | -21.59 Mn |
| Dec 31, 2025 | -19.37 Mn |
| Dec 31, 2025 | -19.37 Mn |
| Sep 30, 2025 | -21.57 Mn |
| Sep 30, 2025 | -21.57 Mn |
| Jun 30, 2025 | -20.81 Mn |
| Jun 30, 2025 | -20.81 Mn |
| Mar 31, 2025 | -26.87 Mn |
| Mar 31, 2025 | -26.87 Mn |
| Dec 31, 2024 | -19.66 Mn |
| Dec 31, 2024 | -19.66 Mn |
| Sep 30, 2024 | -27.44 Mn |
| Sep 30, 2024 | -27.44 Mn |
| Jun 30, 2024 | -28.21 Mn |
| Jun 30, 2024 | -28.21 Mn |
| Mar 31, 2024 | -28.76 Mn |
| Mar 31, 2024 | -28.76 Mn |